Radka Stoyanova
Professor and Director of Imaging and Biomarkers
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Radka Stoyanova is a Professor and Director of Imaging and Biomarkers at the University of Miami, USA. Her research primarily focuses on the applications of radiomics in prostate cancer radiotherapy and the analysis of dynamic susceptibility contrast (DSC)-MRI for segmenting tissue areas in stroke models. She is dedicated to advancing the understanding of imaging methodologies and their clinical implications in oncology and neurology.
Articles (3)
Purpose: Clinical risk grouping based on PSA, tumor grade, and disease extent guides treatment intensity for localized prostate cancer. However, many patients with intermediate- or high-risk disease treated with external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) still develop biochemical recurrence (BCR). Early identification of patients at high risk for BCR could enable personalized treatment strategies. Experimental Design: We prospectively enrolled 29 patients with intermediate- or high-risk prostate cancer undergoing EBRT and ADT. Pretreatment biopsies ( n = 60) underwent whole-transcriptome microarray and whole-exome sequencing. Patients received multiparametric MRI at baseline and 6 months after treatment, with a median follow-up of 6 years. Gene expression differences between patients with and without BCR were analyzed using pathway tools and validated in external datasets. A novel TGF-β gene signature was derived and tested across multiple cohorts (median follow-up: 5–11 years). Results: TGF-β activity was significantly associated with BCR in the discovery cohort ( P = 0.0081) and correlated with PTEN/TP53 alterations ( P = 0.0246) and baseline multiparametric MRI tumor volume ( P = 0.026). TGF-β activity also predicted metastasis-free survival ( P = 0.037) and, in an independent cohort ( n = 265), was prognostic for BCR-free ( P = 0.05), metastasis-free ( P P Conclusions: TGF-β activity is a dominant feature of intermediate- to unfavorable-risk prostate tumors prone to biochemical failure after EBRT with ADT and may serve as an independent prognostic biomarker beyond existing clinical criteria.
Year:
2025
Year:
2020
Year:
2020
Collaborators (8)
William A. Hall
-
Bradford Wood
Adjunct Professor
University of Maryland
Deborah Citrin
National Cancer Institute
Adam Sowalsky
Senior Investigator
National Cancer Institute
Peter Choyke
Senior Investigator
National Cancer Institute
Peter Pinto
Principal Investigator, Chief Prostate Cancer Section
National Cancer Institute
Rodrigo Delgadillo
University of Miami School of Medicine
Melvin Chua
Professor (with Tenure)
Duke-NUS Medical School
Make your next move.
Prepare your application
Review drafts before you send them.